The share of “Johnson & Johnson” of America jumped by 8% at the end of today’s session, after announcing the approach of developing an anti-vaccine, “Corona”.
The American company stated that it is already approaching the clinical trials of an effective vaccine against the prevalent Corona virus in the world.
The company entered into a billion dollar deal with the US government to create sufficient manufacturing capacity, to provide more than a billion doses of vaccine being tested to fight the emerging corona virus, which has killed at least 34,000 people worldwide.
Johnson & Johnson added that it will start testing this promising vaccine by next September, which is soon compared to what many other companies are planning to start testing potential vaccines within a year and a half.
This, and many pharmaceutical companies in various countries are trying to develop a vaccine against the “Corona” virus, which has infected about 750,000 people and killed nearly 36,000 so far.
In the United States alone, more than 140,000 people have been infected, and government agencies have predicted that the virus can kill about 200,000 Americans.
Johnson & Johnson also revealed that it has committed to allocating more than $ 1 billion in investment alongside the Advanced Biomedical Research and Development Authority (BARDA), a government agency, to co-finance research related to vaccine development, extending previous cooperation.
– .
